Ovid Therapeutics Inc. (OVID)
Develops experimental medicines to treat epilepsy and brain disorders like schizophrenia
$2.36+0.00%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+372.0%
The outlook
OVID trades at $2.36 with unanimous Strong Buy consensus from nine analysts; the average price target sits roughly 132% above the current level. The stock sits about three-quarters of the way up its 52-week range, though its price trend relative to moving averages shows mixed signals.
What’s behind the score
Analyst consensusStrong Buy — 1.0 avg of 9 analysts
Price trendMixed vs its moving averages
52-week range72% of the way from its 52-week low to high
Price targetAvg target +132% vs current price
Analyst price target
~12-month · 9 analysts$5.47average target+131.8% vs now
Now $2.36
Low $4.00High $7.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$440.5M
52-wk high
$3.11
52-wk low
$0.48
50-day avg
$2.47
200-day avg
$2.02
Trailing P/E
—